Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803123 | 0.93 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803523 | 0.91 | MEN1 (0.42) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803527 | 0.91 | ANO1 (0.49) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803179 | 0.87 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803260 | 0.87 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL1954046 | 0.87 | LMNA (0.49) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803608 | 0.82 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14818559 | 0.81 | MEN1 (0.52) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803292 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ANLRP3 | |
| SCHEMBL14803124 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079348-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079348-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079348-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885NPC1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.